194 related articles for article (PubMed ID: 28314176)
1. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.
Lambrescu I; Fica S; Martins D; Spada F; Cella C; Bertani E; Rubino M; Gibelli B; Grana C; Bonomo G; Funicelli L; Ravizza D; Pisa E; Zerini D; Ungaro A; Fazio N;
Cancer Treat Rev; 2017 Apr; 55():46-56. PubMed ID: 28314176
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.
Bocci G; Kerbel RS
Nat Rev Clin Oncol; 2016 Nov; 13(11):659-673. PubMed ID: 27184418
[TBL] [Abstract][Full Text] [Related]
3. Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis.
Arrivi G; Spada F; Frassoni S; Bagnardi V; Laffi A; Rubino M; Gervaso L; Fazio N
J Neuroendocrinol; 2022 Oct; 34(10):e13189. PubMed ID: 36306196
[TBL] [Abstract][Full Text] [Related]
4. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
[TBL] [Abstract][Full Text] [Related]
5. New perspectives in the treatment of neuroendocrine tumours.
Bajetta E; Catena L; Valente M; Bianco N; Bellomo F; Bombardieri E
Anticancer Res; 2012 Oct; 32(10):4193-200. PubMed ID: 23060539
[TBL] [Abstract][Full Text] [Related]
6. Metronomics chemotherapy: time for computational decision support.
Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
[TBL] [Abstract][Full Text] [Related]
7. Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
Petry V; Gagliato DM; Leal AI; Arai RJ; Longo E; Andrade F; Ricci MD; Piato JR; Barroso-Sousa R; Hoff PM; Mano MS
Braz J Med Biol Res; 2015 May; 48(5):479-85. PubMed ID: 25760024
[TBL] [Abstract][Full Text] [Related]
8. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules.
Banchi M; Cox MC; Bocci G
Cancer Lett; 2024 Jun; 591():216900. PubMed ID: 38636896
[TBL] [Abstract][Full Text] [Related]
9. [Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer].
Zhang S; Liu J; Cheng Y
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):232-9. PubMed ID: 25936888
[TBL] [Abstract][Full Text] [Related]
10. Metronomic chemotherapy and nanocarrier platforms.
Abu Lila AS; Ishida T
Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
12. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
[TBL] [Abstract][Full Text] [Related]
13. Metronomic therapy concepts in the management of adrenocortical carcinoma.
Berruti A; Sperone P; Bellini E; Daffara F; Perotti P; Ardito A; Saini A; Terzolo M
Horm Cancer; 2011 Dec; 2(6):378-84. PubMed ID: 21971765
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
Basu B; Sirohi B; Corrie P
Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
Ferdous T; Harada K; Kin T; Harada T; Ueyama Y
Int J Oncol; 2013 Jul; 43(1):271-9. PubMed ID: 23695365
[TBL] [Abstract][Full Text] [Related]
17. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
18. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
[TBL] [Abstract][Full Text] [Related]
19. Metronomic chemotherapy in metastatic colorectal cancer.
Woo IS; Jung YH
Cancer Lett; 2017 Aug; 400():319-324. PubMed ID: 28274890
[TBL] [Abstract][Full Text] [Related]
20. Metronomic chemotherapy and immunotherapy in cancer treatment.
Chen YL; Chang MC; Cheng WF
Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
